Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing — Stella

Home/Stroke/Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing

View on ClinicalTrials.gov

Recruiting

Back to Stroke trials

Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing

Not a traditional drug trial — this study doesn't follow the standard phase structure.

Trial locations(1 site)

United States

University of Alabama at Birmingham, Birmingham, Alabama

Key details

Sponsor

University of Alabama at Birmingham

Enrollment target

~200 participants

Started

April 2025

Primary completion

April 2028

Age range

18 Years – 89 Years

Last updated April 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.